Genmab — August 2017
-
Bryan Garnier hæver kursmålet til 2000 fra 1850
-
-
Bryan G: Taking into account these positive results, we reviewed our Probability of Success for the ALCYONE study and assume that Daratumumab now has a 90% success rate to get FDA/EMA approvals and to reach the market for Multiple Myeloma treatment in front line.
-
-
Citi er meget positive må man sige.
-
-
-
ja det lyder rigtig godt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind